European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease: BioArctic
BioArctic AB's partner Eisai announced today that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of Early Alzheimer's disease with confirmed amyloid pathology, for review following a standard timeline.
Invitation to presentation of BioArctic's fourth quarter report for October - December 2022 on October 20 at 9.30 a.m. CET
BioArctic AB will publish the company's fourth quarter report for October- December 2022 on Friday, February 3, 2022, at 08:00 a.m. CET.. In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference on February 3, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on...
BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in Japan
BioArctic AB's partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia with confirmed presence of amyloid pathology in the brain to the...